Personalis Cost of Goods Sold 2018-2024 | PSNL

Personalis cost of goods sold from 2018 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
Personalis Annual Cost of Goods Sold
(Millions of US $)
2023 $55
2022 $52
2021 $54
2020 $59
2019 $43
2018 $26
2017 $12
Personalis Quarterly Cost of Goods Sold
(Millions of US $)
2024-09-30 $17
2024-06-30 $15
2024-03-31 $14
2023-12-31 $14
2023-09-30 $15
2023-06-30 $12
2023-03-31 $14
2022-12-31 $14
2022-09-30 $12
2022-06-30 $14
2022-03-31 $11
2021-12-31 $13
2021-09-30 $14
2021-06-30 $14
2021-03-31 $13
2020-12-31 $14
2020-09-30 $14
2020-06-30 $15
2020-03-31 $15
2019-12-31 $12
2019-09-30 $12
2019-06-30 $10
2019-03-31 $10
2018-12-31
2018-09-30 $7
2018-06-30 $6
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.245B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Taysha Gene Therapies (TSHA) United States $0.506B 35.29
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00